Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 1,701–1,800 of 4,108
Lin, Y.-H., Shih, Y.-T., & Teng, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105256 · Cited by 14
“5 SD < T-score < −1 SD) and a 10-year risk of major osteoporotic fracture ≥20% or risk of hip fracture ≥3% are considered a high-risk group, and treatment should be initiated [16].”
BackgroundZhao, Y., Zhao, W., Hao, Q., Ge, M., Zhang, Y., Hu, F., Lu, Y., Zhou, L., Liu, X., & Dong, B. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02449-7 · Cited by 12
“Although the exact reason for the high prevalence of vitamin D insufficiency and deficiency in China is uncertain, the low nutritional intake of vitamin D and sunavoidance behaviors by older adults might be contributing factors [26, 27].”
BackgroundKurtz, M., Desquilbet, L., Maire, J., et al. (2022) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.16508 · Cited by 11
“Intact (1-84) PTH was measured by ELISA (Immutopics International, San Clemente, California).”
MethodCurrent issues in evaluation and management of osteoporosis in Thailand
Charoenngam, N., & Pongchaiyakul, C. (2023) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2023.05.002 · Cited by 15
“It is recommended that not only patients with osteoporosis, but also some individuals at risk whose BMD does not meet the threshold, be evaluated for asymptomatic vertebral fractures using vertebral imaging (ie, lateral spine X-ray or vertebral fracture assessment with DXA) [64,65].”
BackgroundCheng, X., Li, D., & Cui, R. (2023) · Journal of Engineering Research · doi:10.1016/j.jer.2023.100151 · Cited by 14
Barańska, A., Drop, B., Religioni, U., Dolar-Szczasny, J., Malm, M., Wdowiak, K., Bogdan, M., Kłak, A., Merks, P., & Ręjdak, R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196157 · Cited by 16
Osteoporosis in the setting of rotator cuff repair: A narrative review
Daher, M., Zalaquett, Z., Fares, M. Y., Boufadel, P., Khanna, A., & Abboud, J. A. (2023) · Shoulder & Elbow · doi:10.1177/17585732231207338 · Cited by 14
Human Immunodeficiency Virus in Older Adults
Russell, M. L., & Justice, A. C. (2024) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2023.12.004 · Cited by 12
End-to-End Semi-Supervised Opportunistic Osteoporosis Screening Using Computed Tomography
Oh, J. E., Kim, B., Oh, G., Hwangbo, Y., & Ye, J. C. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1860 · Cited by 16
Silva, D. D., Crous, A., & Abrahamse, H. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070379 · Cited by 11
Li, X., Liu, Y., Chen, X., Reichetzeder, C., Elitok, S., Krämer, B. K., & Hocher, B. (2024) · Nutrients · doi:10.3390/nu16162679 · Cited by 15
Je, M., Hwang, S., Lee, S., & Kim, Y. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03669-4 · Cited by 16
Silverman, S. L., Komm, B. S., & Mirkin, S. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.07.007 · Cited by 11
Wong, T. H., Gupta, E., Radhakrishnan, A. K., Gun, S. C., Chembalingam, G., & Yeap, S. S. (2017) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13048 · Cited by 11
Impact of FRAX-based osteoporosis intervention using real world data
Goldshtein, I., Ish‐Shalom, S., & Leshno, M. (2017) · Bone · doi:10.1016/j.bone.2017.07.027 · Cited by 12
Tonon, M., Piano, S. S., Romano, A., Fasolato, S., Stanco, M., Pilutti, C., Pontisso, P., Mareso, S., Gambino, C. G., Sartori, L., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001051 · Cited by 11
The Effectiveness of Osteoporosis Screening and Treatment in the Midwest
Patel, D. S., Worley, J. R., Volgas, D. A., & Crist, B. D. (2018) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151459318765844 · Cited by 11
Vrathasha, V., Booksh, K. S., Duncan, R. L., & Nohe, A. (2018) · Nanomaterials · doi:10.3390/nano8070513 · Cited by 11
Association between abdominal obesity and fragility fractures among elderly Israeli women
Ofir, O., Buch, A., Rouach, V., Goldsmith, R., Stern, N., & Ornan, E. M. (2019) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01347-8 · Cited by 13
Comparison of screening tools for optimizing fracture prevention in Canada
Leslie, W. D., Lix, L. M., & Binkley, N. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00846-w · Cited by 11
Classification Criteria and Clinical Practice Guidelines for Rheumatic Diseases
Hassan, R., Faruqui, H. M., Alquraa, R., Eissa, A., Alshaiki, F., & Cheikh, M. (2021) · Springer eBooks · doi:10.1007/978-981-15-8323-0_25 · Cited by 21
Differential impact of osteoporosis, sarcopenia and obesity on physical performance in aging men
Genest, F., Schneider, M., Zehnder, A., Lieberoth-Leden, D., & Seefried, L. (2021) · Endocrine Connections · doi:10.1530/ec-20-0580 · Cited by 14
Tripto‐Shkolnik, L., Vered, I., Peltz-Sinvani, N., Kowal, D., & Goldshtein, I. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2020.12.010 · Cited by 11
Health Benefits and Risks of Minerals: Bioavailability, Bio-Essentiality, Toxicity, and Pathologies
Gomes, C., & Silva, E. A. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-65706-2_4 · Cited by 19
Pineda‐Moncusí, M., Elhussein, L., Delmestri, A., Cooper, C. C., Moayyeri, A., Libanati, C. R., Tóth, E., Prieto‐Alhambra, D., & Khalid, S. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4648 · Cited by 15
“(32) Candidate risk factors The overall set of variables considered for inclusion in the prediction model contained risk factors from the QRISK model,(12) as well as additional risk factors identified in the literature as being potentially associated with CVD.(15-17,20,21,33-41) These included sociodemographic and lif…”
BackgroundInfluentialOsteoporotische Wirbelkörperfrakturen – Von der Diagnose zur Therapie
Benditz, A., & Jerosch, J. (2022) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-022-01255-9 · Cited by 11
Haeri, N. S., Perera, S., & Greenspan, S. L. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.54 · Cited by 11
Chuang, T., Chuang, M., Wang, Y., & Koo, M. (2022) · Medicina · doi:10.3390/medicina58121766 · Cited by 16
Lo, J. C.-M., Chandra, M., Lee, D. R., Darbinian, J. A., Gordon, N. P., Zeltser, D. W., Grimsrud, C. D., & Lee, C. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18242 · Cited by 12
Controlling Nutritional Status score and postmenopausal osteoporosis
Köse, C., Körpe, B., İbanoğlu, M. C., Şahin, B., & Üstün, Y. E. (2023) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002175 · Cited by 13
Kanat, B. B., Avcı, G. U., Bayramlar, O. F., Unal, D., Sönmez, Ö., Bolayırlı, M., Döventaş, A., Erdinçler, D. S., & Yavuzer, H. (2023) · Annals of Geriatric Medicine and Research · doi:10.4235/agmr.23.0024 · Cited by 11
Kirk, B., Harrison, S. L., Zanker, J., Burghardt, A. J., ORWOLL, E. S., Duque, G., & Cawthon, P. M. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4874 · Cited by 12
“Our population was also limited to men, and therefore our findings cannot be extrapolated to women, who are at higher risk of fractures((32)) and have different body composition than men.”
ResultKara, G. K., & Öztürk, Ç. (2023) · Acta Orthopaedica et Traumatologica Turcica · doi:10.5152/j.aott.2023.23099 · Cited by 14
Knowledge, Attitude, and Behavior Levels of Postmenopausal Women about Osteoporosis
Saltık, H., Öztürk, F., Emiroğlu, C., Hekįmoğlu, B., & Aypak, C. (2023) · Journal of Bone Metabolism · doi:10.11005/jbm.2023.30.4.347 · Cited by 19
“[4] Osteoporosis and accompanying fractures increase mortality and morbidity, especially when they occur in the hip and spine regions.”
BackgroundBisphosphonates vs Exercise for the Prevention and Treatment of Osteoporosis
Hurley, B. F., & Armstrong, T. (2012) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2011.07.029 · Cited by 11
Lee, S., Choi, M. G., Yu, J., Ryu, O., Yoo, H. J., Ihm, S., Kim, D. M., Hong, E. G., Park, K. T., Choi, M.-J., et al. (2015) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-015-0523-4 · Cited by 12
Chiu, C., Kuo, M., Yu, S., Su, Y., & Cheng, T. (2013) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-14-276 · Cited by 11
Grover, M. L., Anderson, M., Gupta, R., Haden, M., Hartmark-Hill, J. R., Morski, L. M., Sarmiento, P., & Dueck, A. C. (2009) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2009.06.090040 · Cited by 10
López, E., Ibarz, E., Herrera, A., Mateo, J., Lobo-Escolar, A., Puértolas, S., & Gracia, L. (2012) · BioMedical Engineering OnLine · doi:10.1186/1475-925x-11-84 · Cited by 11
COPD: osteoporosis and sarcopenia
Majid, H., Kanbar-Agha, F., & Sharafkhaneh, A. (2016) · COPD Research and Practice · doi:10.1186/s40749-016-0019-0 · Cited by 14
Measurement and Clinical Utility of βCTX in Serum and Plasma
Chubb, S. A. P., & Vasikaran, S. D. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.01.003 · Cited by 12
Reniu, A. C., Ong, T. I. W., Ajmal, S., et al. (2017) · Archives of Osteoporosis · doi:10.1007/s11657-017-0318-3 · Cited by 11
Transgender Individuals and Osteoporosis Prevention
Sedlak, C. A., Roller, C. G., van Dulmen, M. H. M., Alharbi, H. A., Sanata, J. D., Leifson, M. A., Veney, A. J., Alhawatmeh, H. N., & Doheny, M. O. (2017) · Orthopaedic Nursing · doi:10.1097/nor.0000000000000364 · Cited by 11
Tremblay, D. A., Patel, V. G., Fifer, K. M., et al. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3834-1 · Cited by 11
İmerci, A., Kilinç, C. Y., Aydoğan, N. H., Karalezli, M. N., & Savran, A. (2017) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2017.06.027 · Cited by 12
Weaver, J. P., Olsson, K., Sadasivan, R., Modi, A., & Sen, S. S. (2017) · Journal of Women s Health · doi:10.1089/jwh.2016.6263 · Cited by 13
Ren, H., Sun, R., & Wang, J. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.5857 · Cited by 12
Bone turnover markers are differentially affected by pre-analytical handling
Christensen, G. L., Halgreen, J. R., Milenkovski, M., Köse, A., Quardon, N., & Jørgensen, N. R. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04837-7 · Cited by 11
Gates, M., Pillay, J., Thériault, G., Limburg, H., Grad, R. M., Klarenbach, S. W., Korownyk, C. S., Reynolds, D. L., Riva, J. J., Thombs, B. D., et al. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1094-5 · Cited by 13
“The United States National Osteoporosis Foundation [70] recommends initiating pharmacological treatment in individuals with osteoporosis or with low BMD (T-score between − 1.0 and − 2.5, osteopenia) and either a 10-year hip fracture probability ≥ 3% or a 10- year major osteoporosis-related fracture probability ≥ 20% (…”
BackgroundInfluentialIbrahim, N., Nabil, N., & Ghaleb, S. (2019) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_4_19 · Cited by 15
Rodríguez‐Martín, S., González‐Bermejo, D., Rodríguez, A., Barreira, D., García‐Lledó, A., Gil, M., & de Abajo, F. J. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1636 · Cited by 11
“Despite calcium being ubiquitous in foods, the recommended daily amounts are often not met making its supplementation a common practice, in particular among women as first-line therapy to prevent osteoporotic fractures, in whom clear benefits have been shown.(2) However, the benefit-risk ratio of this practice has bee…”
BackgroundResultSpinal cord injury providers’ perspectives on managing sublesional osteoporosis
Weaver, F. M., Etingen, B., Guihan, M., Ray, C. E., Priebe, M. M., Burns, S. P., & Carbone, L. D. (2019) · Journal of Spinal Cord Medicine · doi:10.1080/10790268.2019.1704552 · Cited by 12
Osteoporosis and fragility fractures: risk assessment, management and prevention
Walker, J. A. (2019) · Nursing Older People · doi:10.7748/nop.2019.e1153 · Cited by 12
Targeted vertebral fracture assessment for optimizing fracture prevention in Canada
Leslie, W. D., Lix, L. M., & Binkley, N. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00735-2 · Cited by 9
Lee, S.-M., Seo, J.-S., Kwak, S., Shin, W. C., Bae, J., & Woo, S.-H. (2020) · Injury · doi:10.1016/j.injury.2020.03.063 · Cited by 10
Li, X., Xu, Y., Lin, W., & Fan, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-70144-5 · Cited by 12
Pumberger, M., Issever, A. S., Diekhoff, T., Schwemmer, C., Berg, S., Palmowski, Y., & Putzier, M. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01895-0 · Cited by 11
Yan, Y., Chen, W., Wang, J., Jing, H., Lv, J., Zhao, H., & Guo, L. (2020) · Biomarkers · doi:10.1080/1354750x.2020.1833083 · Cited by 12
Chisati, E. M., Constantinou, D., & Lampiao, F. (2020) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-020-00216-6 · Cited by 13
Jiang, H., Deng, R., Deng, Y., Nie, M., Deng, Y., Luo, H., Yang, Y., Ni, N., Ran, C.-C., & Deng, Z. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02347-0 · Cited by 11
“GIOP patients with fractures are susceptible to delayed bone union and nonunion [12].”
BackgroundNowakowska-Płaza, A., Wroński, J., Płaza, M., Sudoł‐Szopińska, I., & Głuszko, P. (2021) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16046 · Cited by 15
Race and Age Impact Osteoporosis Screening Rates in Women Prior to Hip Fracture
Benes, G. A., David, J., Synowicz, M., Betech, A., Dasa, V., Krause, P. C., Jones, D. G., Hall, L., Leslie, L., & Chapple, A. G. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01076-y · Cited by 11
Thyroid Nodules and Cancer in the Elderly
Lechner, M. G., & Hershman, J. M. (2015) · Cited by 14
Bone Health Care for Patients With Prostate Cancer Receiving Androgen Deprivation Therapy
Tsang, D. S., & Alibhai, S. M. H. (2014) · Hospital Practice · doi:10.3810/hp.2014.04.1107 · Cited by 12
Osteoporosis, osteopenia and fracture risk: Widening the therapeutic horizons
Davey, D. A. (2012) · South African Medical Journal · doi:10.7196/samj.5400 · Cited by 14
Low-Level Cadmium Exposure and Bone Health
Xie, D., & Sheng, Z. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3049 · Cited by 11
Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients
Moldovan, D. T., Rusu, C. C., Potra, A. R., Moldovan, I., Pațiu, I. M., Gherman-Căprioară, M., & Kacsó, I. M. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1529-7 · Cited by 12
Vytrisalova, M., Touskova, T. P., Fuksa, L., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00258 · Cited by 11
Nakatsukasa, K., Koyama, H., Ouchi, Y., Sakaguchi, K., Fujita, Y., Matsuda, T., Kato, M., Konishi, E., & Taguchi, T. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s167579 · Cited by 11
Hurley, D. L., Binkley, N., Camacho, P. M., Diab, D. L., Kennel, K. A., Malabanan, A. O., & Tangpricha, V. (2018) · Endocrine Practice · doi:10.4158/ps-2018-0050 · Cited by 12
McCaleb, R. V., & Johnson, J. T. (2018) · AACE Clinical Case Reports · doi:10.4158/accr-2018-0295 · Cited by 11
Chen, X., Zhang, C., Li, J., Liu, W., Zhang, J., & Zhou, Z. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s274614 · Cited by 15
Dowhan, L., & Dharmarajan, T. S. (2021) · Springer eBooks · doi:10.1007/978-3-319-90761-1_26-1 · Cited by 17
Panoramic Radiomorphometric Indices of Mandible: Biomarker for Osteoporosis
Govindraju, P., Kumar, T. S. M., Chandra, P., Balaji, P., & Sowbhagya, M. B. (2015) · Exposure and Health · doi:10.1007/978-94-007-7745-3_13-1 · Cited by 11
Osteoporosis and Silent Vertebral Fractures in Nursing Home Resident Elderly Men in Turkey
Küçükler, F. K., Şimşek, Y., Türk, A. Ç., Arduç, A., & Güler, S. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.05.064 · Cited by 16
Primary Care of the Human Immunodeficiency Virus Patient
Buckhold, F. R. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.05.010 · Cited by 12
Cesme, F., Esmaeilzadeh, S., & Oral, A. (2016) · Acta Orthopaedica et Traumatologica Turcica · doi:10.1016/j.aott.2016.08.006 · Cited by 12
Cui, J., Liu, C. L., Jennane, R., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1054991 · Cited by 10
“However, at the early stages of osteoporosis, bone loss happens at individual trabecular plates (Cosman et al., 2014; Golob and Laya, 2015), so our pixel-wise feature counting has the potential for early diagnosis of osteoporosis.”
BackgroundMatsumoto, T., Sone, T., Yamashita, A., et al. (2023) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-023-01455-6 · Cited by 10
Rastogi, S. K., Khanka, S., Kumar, S., Lakra, A., Rathur, R., Sharma, K., Bisen, A. C., Bhatta, R. S., Kumar, R., Singh, D. R., et al. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00500c · Cited by 10
Liao, C., He, D., Yin, K., Lin, Y., Chen, Y., Zhang, Z., Zhang, J., Luo, H., Chen, X., & Li, Y. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02410e · Cited by 11
Yamamoto, K., & Tanaka, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102806 · Cited by 10
Pan, J., Lin, P., Gong, S., Wang, Z., Cao, R., Lv, Y., Zhang, K., & Wang, L. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01455-7 · Cited by 15
“We collected some clinically significant risk factors for osteoporosis in the same period that CT scans were performed [24], including (1) general subject data: age, sex, height, weight, blood pressure (systolic blood pressure, diastolic blood pressure), and body mass index (BMI), calculated as…”
The influence of severity of hemophilia on bone mineral density and fracture risk
Ransmann, P., Hmida, J., Brühl, M., Schildberg, F. A., Goldmann, G., Oldenburg, J., Jaenisch, M., Tomschi, F., Hilberg, T., & Strauss, A. C. (2024) · Research and Practice in Thrombosis and Haemostasis · doi:10.1016/j.rpth.2024.102624 · Cited by 12
Inpan, R., Dukaew, N., Takuathung, M. N., Teekachunhatean, S., & Koonrungsesomboon, N. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01467-3 · Cited by 13
“However, when combined with other treatments high risk; some concerns; low risk like estradiol, SERMs, or isoflavones, calcium and vitamin D can contribute to a more holistic approach to bone health, potentially enhancing the overall therapeutic effect [34].”
Ali, D. S., Mirza, R. D., Hussein, S., Alsarraf, F., Alexander, R. T., Alrob, H. A., Appelman‐Dijkstra, N. M., Duplan, M. B., Brandi, M. L., Carpenter, T. O., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf011 · Cited by 13
Self-citationA Clinician Performance Initiative to Improve Quality of Care for Patients with Osteoporosis
Greenspan, S. L., Bilezikian, J. P., Watts, N. B., et al. (2013) · Journal of Women s Health · doi:10.1089/jwh.2013.4388 · Cited by 10
Tawil, R., Mah, J. K., Baker, S., Wagner, K. R., Ryan, M. M., Baker, S., Corbett, A., van Engelen, B. G. M., McNamara, S., Mah, J. K., et al. (2016) · Neuromuscular Disorders · doi:10.1016/j.nmd.2016.03.007 · Cited by 11
Artifacts Affecting Dual-Energy X-Ray Absorptiometry Measurements
Spiro, A. J., Hoang, T. D., & Shakir, M. K. M. (2019) · AACE Clinical Case Reports · doi:10.4158/accr-2019-0031 · Cited by 14
Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
Patel, U., & Caulfield, S. E. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.5.8 · Cited by 11
Le, Q. A. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.10.1089 · Cited by 12
Association of sepsis with risk for osteoporosis: a population-based cohort study
Lee, Y., Tsou, H., Leong, P., Wang, Y.-H., & Wei, J. C. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05599-3 · Cited by 10
Dussault, P. M., McCarthy, D., Davis, S. A., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05926-2 · Cited by 10
Use of an electronic medical record dashboard to identify gaps in osteoporosis care
Παπαϊωάννου, Α., McCloskey, E. V., Bell, A., Ngui, D., Mehan, U., Tan, M., Goldin, L., & Langer, A. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00919-4 · Cited by 12
Access to care for low trauma hip fractures in South Africa
Dela, S. S., Paruk, F., Conradie, M., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01057-1 · Cited by 10
“Dual-energy X-ray absorptiometry (DXA) and fracture risk assessment models improve identification of persons at risk of hip and other major osteoporotic fractures [1–4] and new medications for osteoporosis reduce fracture risk [5, 6].”
BackgroundOkoye, C., Calsolaro, V., Niccolai, F., Calabrese, A. M., Franchi, R., Rogani, S., Coppini, G., Morelli, V., Caraccio, N., & Monzani, F. (2022) · Geriatrics · doi:10.3390/geriatrics7010013 · Cited by 10
Yu, D., Chen, W., Zhang, J., Wei, L., Qin, J., Lei, M., Tang, H., Wang, Y., Xue, S., Dong, J., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01815-5 · Cited by 15
Influence of lifestyle factors on bone metabolism and the risk of osteoporosis
Galchenko, A. V. (2022) · Russian Journal of Preventive Medicine · doi:10.17116/profmed20222506196 · Cited by 11
Effects of osthole on osteoporotic rats: a systematic review and meta-analysis
Wu, B., Zhu, X., Yang, X., Wang, W., & Lu, J.-H. (2022) · Pharmaceutical Biology · doi:10.1080/13880209.2022.2110267 · Cited by 10
“2020), and impaired gastrointestinal and renal functions (Cosman et al. 2014).”
BackgroundInfluentialBibliometric and visualized analysis of exercise and osteoporosis from 2002 to 2021
Li, F., Xie, W., Han, Y., Li, Z., & Xiao, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.944444 · Cited by 10
“In 2014, the guideline (10), developed by the National Osteoporosis Foundation, recommended weightbearing and muscle-strengthening exercise to maintain or improve bone strength.”
Background
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.